Charts

Gainers OncoCyte (NASDAQ:OCX) stock increased by 57.5% to $0.31 during Thursday's regular session. Trading volume for this security as ...

According to Benzinga Pro data, during Q4, Baudax Bio (NASDAQ:BXRX) posted sales of $310 thousand. Earnings were up 68.33%, but Baudax ...

Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results Expected Early Q2 2023 BX2000 Dose Escalation Study Progressing $5 Million in Financing Secured through Public Offering MALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital a

Gainers Owlet (NYSE:OWLT) stock rose 32.0% to $0.45 during Friday's after-market session. Owlet's trading volume hit 1.5 million shares ...

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced ...

Gainers Geovax Labs (NASDAQ:GOVX) shares moved upwards by 62.8% to $1.14 during Wednesday's regular session. As of 12:30 EST, Geovax ...

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 80.0% to $2.16 during Wednesday's pre-market session. The company's market cap ...

U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 80 points on Tuesday. The Dow traded up 0.24% ...

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim ...

Gainers bioAffinity Technologies (NASDAQ:BIAF) shares increased by 115.1% to $3.42 during Tuesday's regular session. Trading volume for ...

After a strong start to the week, stocks are struggling for direction today as investors unpack the latest batch of earnings reports.

U.S. stocks traded mostly flat midway through trading, with the Dow Jones trading slightly higher on Tuesday. The Dow traded up 0.03% ...

Baudax Bio Inc(NASDAQ: BXRX)announced the outcomeof its first interim analysis in a Phase 2 trial of BX1000 for ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BXRX stock is soaring today as Baudax Bio's novel medical product could result in time and cost savings for patients and hospitals. The post Why Is Baudax Bio (BXRX) Stock Up 50% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Tuesday. Following the market opening ...

Gainers Axcella Health (NASDAQ:AXLA) shares rose 64.0% to $0.71 during Tuesday's pre-market session. The market value of their ...

MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the successful outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. “We are encouraged by the results of the first interim analysis of the BX1000 Phase II surgery trial,” said Gerri Henwood, Baudax Bio’s President and Chief E

Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock rose 8.3% to $0.2 during Tuesday's after-market session. Today's trading volume ...

Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares rose 105% to $0.41 in pre-market trading after the company requested to ...

Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for ...

U.S. stocks traded higher this morning, with the Dow Jones gaining around 250 points on Thursday. Following the market opening ...

Gainers Quotient (NASDAQ:QTNT) stock moved upwards by 114.0% to $0.49 during Thursday's pre-market session. The market value of their ...

Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. ...

Gainers Quotient (NASDAQ:QTNT) stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With 2022 rapidly coming to a close, it’s time to take a look back at the most sold-off stocks so you know which names to avoid. The post The 7 Most Sold-Off Stocks of 2022 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after ...

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 296% to $3.71 after the company announced interim results from the ...

Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim ...

On Wednesday, 115 stocks hit new 52-week lows. Noteable 52-Week Lows: The largest company by market cap to hit a new ...

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ...

Gainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG ...

Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) stock rose 164.8% to $1.43 during Monday's regular session. Trading volume for HTG ...

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares rose 104% to $7.00 in pre-market trading. Aptevo Therapeutics said 100% ...

Gainers HTG Molecular Diagnostics (NASDAQ:HTGM) stock moved upwards by 170.4% to $1.46 during Monday's pre-market session. The market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results ...

Gainers Ambrx Biopharma (NYSE:AMAM) stock increased by 583.1% to $2.8 during Friday's regular session. The current volume of 68.6 ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Boeing (BA) stock fans will want to keep an eye on the company when Dec. 13 rolls around as it has a "historic announcement" to make. The post Dear Boeing (BA) Stock Fans, Mark Your Calendars for a ‘Historic Announcement’ on Dec. 13 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

U.S. stocks traded slightly lower this morning following the release of PPI data Following the market opening Friday, the Dow traded ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Baudax Bio (BXRX) stock is rocketing higher on Friday after the pharmaceutical company initiated a Phase 2 clinical trial of BX1000. The post Why Is Baudax Bio (BXRX) Stock Up 46% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Baudax Bio (NASDAQ:BXRX) stock moved upwards by 61.2% to $6.56 during Friday's pre-market session. The company's market cap ...

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 48.2% to $6.03 in pre-market trading after jumping over 20% on Thursday. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. This randomized, double-blind clinical trial will study BX1000 in approximately 80 adult patients, 18-65 years of age, who u

MALVERN, Pa., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related settings, today announced the closing of its previously announced public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of

MALVERN, Penn., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of a public offering of an aggregate of 1,042,787 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public of

On Friday, 72 companies hit new 52-week lows. Interesting Points From Today's 52-Week Lows: Lucid Gr ...

MALVERN, Pa., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced that the Company’s Board of Directors has approved a 1-for-40 reverse stock split of its common shares (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on December 1, 2022 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a po

Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on ...

On Monday, 79 companies reached new 52-week lows. Facts of Interest About Today's 52-Week Lows: The company with ...

BX 1000 Phase II Trial Underway BX 2000 Dose Escalation Study Progressing ANJESO® Vials Sold to End Users Up 16% Third Quarter Year-Over-Year USPTO Issues Note of Allowance for additional Orange Book Listable ANJESO® Patent MALVERN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the three and nine months ended September 30, 2022,

MALVERN, Pa., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on September 29, 2022. The shares

MALVERN, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the 24th Annual H.C. Wainwright Healthcare Conference, taking place in New York, New York on Wednesday, September 14, 2022 at 3:00 p.m. Eastern Time. A webcast of the presentation will be available on the “Events” page within the inv

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of its previously announced public offering of an aggregate of 11,819,172 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $0.525 per share (or pre-funded warrant) and accompa

MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of its public offering of an aggregate of 11,819,172 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $0.525 per share (or pre-funded warrant) and accompanying warrants. Each s

MALVERN, Pa., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced today that the United States Patent and Trademark Office (“USPTO”) has provided a Notice of Allowance for patent application No. 16/297,095, titled “Methods of administering intravenous meloxicam in a bolus dose”, which includes claims covering the use of multiple doses of ANJESO® for the treatment of moderate to severe pain resulting

ANJESO® Net Product Revenue Up 49% Year-Over-Year; Vials Sold to End-Users Up 67% Year-Over-Year Dosing Complete in the First Cohort of the Phase I BX2000 Study; On Track to Complete Enrollment in Remaining Cohorts by Early 2023 MALVERN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today reported financial results for the three and six months ended June 30, 2022, provided ke

MALVERN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for acute care settings, today announced that the first cohort has been dosed in a First-in-Man, Phase 1 clinical study evaluating the safety, tolerability and pharmacokinetics of BX2000, a rapid onset, ultra-short acting neuromuscular blocking (NMB) agent, in healthy volunteers. This double-blind, placebo-controlled study will investigate single ascending doses

MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the H.C. Wainwright Annual Global Life Sciences Conference, taking place in Miami, Florida on Wednesday, May 25, 2022, at 1:30 p.m. Eastern Time. A webcast of the presentation will be available on the “Events” page within the investors

MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 1,646,091 shares of its common stock, at a purchase price of $1.215 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed to issue to the in

Annual Meeting to be reconvened on May 18, 2022MALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has adjourned its 2022 Annual Meeting of Shareholders (the “Annual Meeting”), without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m.

ANJESO® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth First Cohort Dosed in Pediatric ANJESO Surgical Study Management to Host Investor Conference Call and Webcast Tomorrow at 8:30 a.m. ET MALVERN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today reported financial results for the three months ended March 31, 2

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. Baudax Bio will host a conference call and webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and recent operational highlights. To access the conference call, please dial (866) 220-5595 (local) or (615) 622-8

MALVERN, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Noble Capital Markets’ 18th Annual Investor Conference (NobleCon18), taking place in Hollywood, Florida on Wednesday, April 20, 2022, at 3:30 p.m. Eastern Time. A webcast of the presentation will be